Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells

Molecular Carcinogenesis

Volumn 49, Issue 10, 2010, Pages 892-901

  Laezza, Chiara ^a,b   Malfitano, Anna M ^c   Di Matola, Tiziana ^d   Ricchi, Paolo ^e   Bifulco, Maurizio ^a  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d Centro Traumatologico Ortopedico ASLNA1   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

Author keywords

Apoptosis; N6 isopentenyladenosine; NF B pathway

Indexed keywords

6 N (3,3 DIMETHYLALLYL)ADENOSINE; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; CDK2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL CYCLE; CELL NUCLEUS; CELL SURVIVAL; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; CYTOCHROMES C; FEMALE; HUMANS; ISOPENTENYLADENOSINE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 77958144549     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20666     Document Type: Article

References (40)

1. 6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1. Int J Cancer 2009; 124: 1322-1329.
2. 6-isopentenyladenosine: An emerging anticancer drug. Anticancer Agents Med Chem 2008; 8: 200-204.
3. Mittelman A, Evans JT, Cheda GB. Cytokinins as chemotherapeutic agents. Ann NY Acad Sci 1975; 255: 225-234.
4. Meisel H, Gunther S, Martin D, Schlimme E. Apoptosis induced by modified ribonucleosides in human cell culture systems. FEBS Lett 1998; 433: 265-268.
5. Ishii Y, Hori Y, Sakai S, Honma Y. Control of differentiation and apoptosis of human myeloid leukemia cells by cytokinins and cytokinin nucleosides, plant redifferentiation-inducing hormones. Cell Growth Differ 2002; 13: 19-26.
6. Kersten H. On the biological significance of modified nucleosides in tRNA. Prog Nucleic Acid Res Mol Biol 1984; 31: 59-114.
7. 6-isopentenyladenosine affects cAMP-dependent microfilament organization in FRTL-5 thyroid cells. Exp Cell Res 1997; 234: 178-182.
8. 6-isopentenyladenosine arrests tumour cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation. FASEB J 2006; 20: 412-418.
9. Haefner B. NF-κB: Arresting a major culprit in cancer. Drug Discov Today 2002; 7: 653-663.
10. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883-888.
11. Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002; 16: 1053-1068.
12. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466.
13. Aggarwal BB. Nuclear factor-kappaB: The enemy within. Cancer Cell 2004; 6: 203-208.
14. Rahman KW, Sarkar FH. Inhibition of nuclear translocation of nuclear factor-kB contributes to 3, 3-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 2005; 65: 364-371.
15. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-85.
16. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107: 241-246.
17. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
18. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000; 18: 621-663.
19. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
20. 6-isopentenyladenosine: A potential therapeutic agent for a variety of epithelial cancers. Int J Cancer 2007; 120: 2744-2748.
21. 6-isopentenyladenosine. Int J Cancer 2009; 124: 2179-2185.
22. Wang CY, Cusak JC, Jr., Liu R, Baldwin AS, Jr. Control of inducibile chemoresistance: Enhanced antitumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5: 412-417.
23. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13: 738-747.
24. Yang F, Tang E, Guan K, Wang CY. IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 2003; 170: 5630-5635.
25. Mattioli I, Sebald A, Bucher C, et al. Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappa B kinase beta and controls the kinetics of p65 nuclear import. J Immunol 2004; 172: 6336-6344.
26. Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 1999; 19: 4798-4805.
27. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through downregulation of I(kappa)B(alpha) kinase and nuclear factor kappaB-regulated gene products. Cancer Res 2005; 65: 9555-9565.
28. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
29. Reed JC. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997; 34: S9-S19.
30. Stennicke HR, Salvesen GS. Caspases-Controlling intracellular signals by protease zymogen activation. Biochim Biophys Acta 2000; 1477: 299-306.
31. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999; 68: 383-424.
32. Deveraux QL, Reed JC. IAP family proteins-Suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
33. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999; 18: 5242-5251.
34. Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-κB and IκB alpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 2004; 279: 47148-47158.
35. Mathas S, Lietz A, Janz M, et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102: 1028-1034.
36. Olsen LS, Hjarnaa PJ, Latini S, et al. Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int J Cancer 2004; 111: 198-205.
37. Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 2001; 61: 4901-4909.
38. Meng F, Liu L, Chin PC, D'Mello SR. Akt is a downstream target of NF-kappa B. J Biol Chem 2002; 277: 29674-29680.
39. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-2224.
40. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999; 9: 601-604.